Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Schwab

Showing results (1-10 of 671) with videos related to

Pageof 68
Sort By:
Pharmacogenetics and Genomics|April 14, 2021
EditorialMatthias Schwab
Gynakologisch-Geburtshilfliche Rundschau|February 11, 2009
[Intrauterine programming of disorders of brain function in later life]Matthias Schwab
Journal of Personalized Medicine|June 24, 2022
Variable Drug-Target Exposure, Tumor Signatures, and Combinatorial Targeted Treatment: Approaches of Personalized Medicine in Breast CancerWerner Schroth, Matthias Schwab
European Journal of Clinical Pharmacology|October 13, 2007
The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substratesOliver Burk, Matthias Schwab
Trends in Pharmacological Sciences|December 7, 2014
Data collection as a barrier to personalized medicineDavid Zakim, Matthias Schwab
British Journal of Clinical Pharmacology|January 23, 2014
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a replyHiltrud Brauch, Matthias Schwab
Advanced Drug Delivery Reviews|November 24, 2004
Topical delivery of therapeutic agents in the treatment of inflammatory bowel diseaseUlrich Klotz, Matthias Schwab
Blood|September 17, 2011
Warfarin pharmacogenetics meets clinical useMatthias Schwab, Elke Schaeffeler
Genome Medicine|December 1, 2012
Pharmacogenomics: a key component of personalized therapyMatthias Schwab, Elke Schaeffeler
British Journal of Clinical Pharmacology|September 17, 2013
Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancerHiltrud Brauch, Matthias Schwab
Pageof 68

Showing results (1-10 of 671) with videos related to

Sort By:
Pageof 68
Pharmacogenetics and Genomics|April 14, 2021
EditorialMatthias Schwab
Gynakologisch-Geburtshilfliche Rundschau|February 11, 2009
[Intrauterine programming of disorders of brain function in later life]Matthias Schwab
Journal of Personalized Medicine|June 24, 2022
Variable Drug-Target Exposure, Tumor Signatures, and Combinatorial Targeted Treatment: Approaches of Personalized Medicine in Breast CancerWerner Schroth, Matthias Schwab
European Journal of Clinical Pharmacology|October 13, 2007
The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substratesOliver Burk, Matthias Schwab
Trends in Pharmacological Sciences|December 7, 2014
Data collection as a barrier to personalized medicineDavid Zakim, Matthias Schwab
British Journal of Clinical Pharmacology|January 23, 2014
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a replyHiltrud Brauch, Matthias Schwab
Advanced Drug Delivery Reviews|November 24, 2004
Topical delivery of therapeutic agents in the treatment of inflammatory bowel diseaseUlrich Klotz, Matthias Schwab
Blood|September 17, 2011
Warfarin pharmacogenetics meets clinical useMatthias Schwab, Elke Schaeffeler
Genome Medicine|December 1, 2012
Pharmacogenomics: a key component of personalized therapyMatthias Schwab, Elke Schaeffeler
British Journal of Clinical Pharmacology|September 17, 2013
Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancerHiltrud Brauch, Matthias Schwab
Pageof 68